Endocrinology & Diabetes — MCQs
On this page
A 24-year-old woman with type 1 diabetes for 6 years is brought to the emergency department by ambulance. She was found collapsed at home. Capillary glucose is 1.8 mmol/L. She is unconscious with GCS 6. IV access is difficult due to obesity. Her partner reports she took her usual insulin dose but missed lunch due to gastroenteritis. What is the most appropriate immediate management?
A 70-year-old man with type 2 diabetes is admitted with acute coronary syndrome. His regular medications include metformin, gliclazide, and atorvastatin. On admission, his HbA1c is 72 mmol/mol. He undergoes successful percutaneous coronary intervention. During his hospital stay, his glucose levels range from 8-14 mmol/L despite withholding gliclazide. Understanding the pathophysiology of hyperglycaemia in acute coronary syndrome, which mechanism primarily explains his elevated glucose levels?
A 58-year-old woman with type 2 diabetes for 9 years, currently on metformin 1g twice daily and empagliflozin 10mg once daily, attends for review. Her HbA1c is 64 mmol/mol. She has a history of ischaemic heart disease with myocardial infarction 2 years ago and chronic heart failure (LVEF 35%). eGFR is 48 ml/min/1.73m². Blood pressure is 142/86 mmHg. Which is the most appropriate addition to her treatment regimen?
A 16-year-old boy presents to the emergency department with a 4-week history of polyuria, polydipsia, and 8 kg weight loss. On examination, he is alert with BMI 19 kg/m². Capillary glucose is 22.4 mmol/L. Urine dipstick shows glucose 3+ and ketones 1+. Venous blood gas shows pH 7.38, bicarbonate 22 mmol/L. Random C-peptide is 180 pmol/L (normal 370-1470). Which autoantibody is most specific for the diagnosis?
A 53-year-old man with type 2 diabetes treated with metformin and sitagliptin has an HbA1c of 69 mmol/mol. His BMI is 32 kg/m² and eGFR is 42 ml/min/1.73m². He has a history of heart failure with reduced ejection fraction diagnosed 2 years ago, currently NYHA class II. Which medication should be added to improve both his glycaemic control and cardiovascular outcomes?
A 36-year-old woman is diagnosed with Graves' disease and started on carbimazole 40mg daily. After 3 weeks, she develops a sore throat and fever. Blood tests show white cell count 1.8 × 10⁹/L with neutrophils 0.4 × 10⁹/L. What is the most appropriate immediate management?
A 61-year-old woman with type 2 diabetes for 13 years presents with numbness in both feet. Examination reveals absent ankle reflexes, reduced vibration sense to the knees bilaterally, and loss of light touch sensation in a stocking distribution. Monofilament testing is abnormal. Foot pulses are palpable. HbA1c is 74 mmol/mol. Which additional investigation is most important to arrange?
A 27-year-old woman with type 1 diabetes is admitted with DKA. After 6 hours of treatment with IV fluids and insulin, her glucose falls to 12.4 mmol/L. Venous blood gas shows pH 7.26, bicarbonate 13 mmol/L, ketones 2.8 mmol/L. What is the most appropriate modification to her management?
A 45-year-old woman with newly diagnosed type 2 diabetes attends for advice. Her HbA1c is 58 mmol/mol, BMI 28 kg/m², and eGFR >90 ml/min/1.73m². She has no other comorbidities. Which additional cardiovascular risk assessment is recommended at diagnosis in all patients with type 2 diabetes?
A 58-year-old man with type 2 diabetes for 11 years attends for annual review. He takes metformin and empagliflozin. HbA1c is 52 mmol/mol. Fundoscopy shows multiple dot and blot haemorrhages and hard exudates within one disc diameter of the fovea in both eyes, but visual acuity is 6/6 bilaterally. What is the classification of his diabetic retinopathy and appropriate management?
Endocrinology & Diabetes UK Medical PG Practice Questions and MCQs
Question 71: A 24-year-old woman with type 1 diabetes for 6 years is brought to the emergency department by ambulance. She was found collapsed at home. Capillary glucose is 1.8 mmol/L. She is unconscious with GCS 6. IV access is difficult due to obesity. Her partner reports she took her usual insulin dose but missed lunch due to gastroenteritis. What is the most appropriate immediate management?
- A. Administer 1mg intramuscular glucagon immediately (Correct Answer)
- B. Establish IV access and give 100ml 20% dextrose
- C. Give 50ml 50% dextrose via intraosseous route
- D. Administer 200ml oral glucose solution via nasogastric tube
- E. Establish IV access and give 150ml 10% dextrose
Explanation: ***Administer 1mg intramuscular glucagon immediately*** - In this emergency with **severe hypoglycemia** (1.8 mmol/L) and an **unconscious patient (GCS 6)** with **difficult IV access**, intramuscular glucagon is the most appropriate and rapid first-line intervention. - Glucagon works by stimulating **hepatic glycogenolysis**, rapidly raising blood glucose levels, and is effective in Type 1 diabetes where liver glycogen stores are usually sufficient. *Establish IV access and give 100ml 20% dextrose* - Attempting to establish IV access in an **obese patient** with difficult veins will cause a critical **delay in treatment** for a patient with a GCS of 6, where time to glucose elevation is paramount. - **20% dextrose** is highly hypertonic and carries a significant risk of **thrombophlebitis** or extravasation injury if administered via a peripheral vein, especially if IV access is challenging. *Give 50ml 50% dextrose via intraosseous route* - **50% dextrose** is generally not recommended in current guidelines due to the high risk of **tissue necrosis** upon extravasation, even with central or intraosseous administration. - While intraosseous access provides rapid entry, it is typically reserved for **extreme resuscitation** when IV access is impossible and other less invasive rapid options like IM glucagon have failed or are contraindicated. *Administer 200ml oral glucose solution via nasogastric tube* - Administering fluids or glucose orally or via an **NG tube** to an **unconscious patient** with a GCS of 6 poses a very high risk of **aspiration pneumonia**. - This method is also significantly slower in onset compared to parenteral routes and is therefore not suitable for immediate management of severe, symptomatic hypoglycemia. *Establish IV access and give 150ml 10% dextrose* - While **10% dextrose** is a preferred concentration for intravenous glucose to minimize vein irritation, the critical issue remains the **difficult IV access** and the subsequent delay in administering life-saving glucose. - **IM glucagon** offers a quicker, non-IV route to raise blood glucose immediately, allowing IV access to be established for subsequent, more sustained glucose infusion if needed.
Question 72: A 70-year-old man with type 2 diabetes is admitted with acute coronary syndrome. His regular medications include metformin, gliclazide, and atorvastatin. On admission, his HbA1c is 72 mmol/mol. He undergoes successful percutaneous coronary intervention. During his hospital stay, his glucose levels range from 8-14 mmol/L despite withholding gliclazide. Understanding the pathophysiology of hyperglycaemia in acute coronary syndrome, which mechanism primarily explains his elevated glucose levels?
- A. Decreased insulin secretion due to beta-cell exhaustion
- B. Increased hepatic glucose production from counter-regulatory hormone release (Correct Answer)
- C. Reduced peripheral glucose uptake from inflammatory cytokines
- D. Impaired incretin effect from acute illness
- E. Direct myocardial damage causing insulin resistance
Explanation: ***Increased hepatic glucose production from counter-regulatory hormone release***- In acute stress like **ACS**, the neuroendocrine response triggers the release of **cortisol**, **catecholamines**, and **glucagon**, which stimulate **gluconeogenesis** and **glycogenolysis**.- This surge in **counter-regulatory hormones** is the primary driver for elevated blood glucose levels during acute critical illness, regardless of prior diabetic control.*Decreased insulin secretion due to beta-cell exhaustion*- **Beta-cell exhaustion** is a chronic progressive feature of type 2 diabetes rather than an acute pathophysiology mechanism triggered by a coronary event.- While secretion may be relatively insufficient for the degree of stress, the acute rise is driven by **hormonal antagonism** rather than sudden beta-cell failure.*Reduced peripheral glucose uptake from inflammatory cytokines*- **Inflammatory cytokines** (like TNF-alpha) do contribute to **peripheral insulin resistance**, but they are a secondary mechanism compared to hepatic output.- While cytokines inhibit **GLUT4** translocation in muscle, the dominant factor in acute hyperglycemia is the massive increase in **glucose production** from the liver.*Impaired incretin effect from acute illness*- The **incretin effect** is chronically impaired in patients with **Type 2 Diabetes**, but this deficiency does not fluctuate acutely to explain surge hyperglycemia in ACS.- This mechanism involves **GLP-1** and **GIP** responses to oral glucose, which is less relevant in the context of a systemic **stress response**.*Direct myocardial damage causing insulin resistance*- **Myocardial injury** results in local metabolic shifts, but it does not directly cause systemic **insulin resistance**.- Systemic insulin resistance in this case is a byproduct of high **circulating catecholamines** and **free fatty acids** rather than the damaged heart tissue itself.
Question 73: A 58-year-old woman with type 2 diabetes for 9 years, currently on metformin 1g twice daily and empagliflozin 10mg once daily, attends for review. Her HbA1c is 64 mmol/mol. She has a history of ischaemic heart disease with myocardial infarction 2 years ago and chronic heart failure (LVEF 35%). eGFR is 48 ml/min/1.73m². Blood pressure is 142/86 mmHg. Which is the most appropriate addition to her treatment regimen?
- A. Increase empagliflozin to 25mg once daily
- B. Add sitagliptin 50mg once daily (Correct Answer)
- C. Add gliclazide 40mg once daily
- D. Add pioglitazone 15mg once daily
- E. Add exenatide 10mcg twice daily
Explanation: ***Add sitagliptin 50mg once daily***- **Sitagliptin** (a **DPP-4 inhibitor**) is a safe and effective option for improving glycemic control. Given her **eGFR of 48 ml/min/1.73m²**, the dose must be reduced to **50mg once daily**.- It is **cardiovascularly neutral** and does not worsen **heart failure**, making it a suitable choice for a patient with a history of **ischaemic heart disease** and **chronic heart failure (LVEF 35%)**, who is already on metformin and empagliflozin.*Increase empagliflozin to 25mg once daily*- While **empagliflozin** provides significant **cardiovascular** and **renal benefits**, increasing the dose from 10mg to 25mg offers minimal additional **HbA1c lowering** when the **eGFR** is below 60 ml/min/1.73m².- The primary **cardioprotective and renoprotective benefits** are largely achieved with the 10mg dose, and the glucose-lowering efficacy of **SGLT2 inhibitors** diminishes with declining renal function.*Add gliclazide 40mg once daily*- **Gliclazide** (a **sulfonylurea**) carries a significant risk of **hypoglycemia** and **weight gain**, which are generally undesirable in patients with established **cardiovascular disease**.- Unlike **SGLT2 inhibitors** or **GLP-1 receptor agonists**, sulfonylureas do not offer additional **cardiovascular or renal protection**, making them a less preferred choice in high-risk patients.*Add pioglitazone 15mg once daily*- **Pioglitazone** (a **thiazolidinedione**) is **contraindicated** in patients with **symptomatic heart failure** or a history of **heart failure (LVEF 35%)** due to its propensity to cause **fluid retention** and exacerbate heart failure.- Despite its benefits in improving insulin sensitivity, the risk of worsening her **cardiac status** outweighs any potential benefits.*Add exenatide 10mcg twice daily*- **Exenatide** (a **GLP-1 receptor agonist**) is generally avoided or used with extreme caution when the **eGFR** is below 50 ml/min/1.73m², and it is **contraindicated** if the eGFR is below 30 ml/min/1.73m². Her **eGFR is 48 ml/min/1.73m²**.- While other GLP-1 receptor agonists have shown cardiovascular benefits, the renal impairment limits the use of **exenatide** and makes **DPP-4 inhibitors** a safer alternative.
Question 74: A 16-year-old boy presents to the emergency department with a 4-week history of polyuria, polydipsia, and 8 kg weight loss. On examination, he is alert with BMI 19 kg/m². Capillary glucose is 22.4 mmol/L. Urine dipstick shows glucose 3+ and ketones 1+. Venous blood gas shows pH 7.38, bicarbonate 22 mmol/L. Random C-peptide is 180 pmol/L (normal 370-1470). Which autoantibody is most specific for the diagnosis?
- A. Anti-islet cell antibodies (ICA)
- B. Anti-zinc transporter 8 (ZnT8) antibodies (Correct Answer)
- C. Anti-glutamic acid decarboxylase (anti-GAD) antibodies
- D. Anti-insulin antibodies (IAA)
- E. Anti-insulinoma antigen-2 (IA-2) antibodies
Explanation: ***Anti-zinc transporter 8 (ZnT8) antibodies*** - These antibodies are considered the **most specific** marker for **Type 1 Diabetes Mellitus (T1DM)** and are particularly useful in differentiating it from other forms of diabetes, especially when other antibodies are negative. - They are present in approximately 60-80% of newly diagnosed cases and can be predictive of **beta-cell destruction** even in the absence of other autoantibodies. *Anti-islet cell antibodies (ICA)* - ICA were historically the first autoantibodies identified but are now largely replaced by more specific assays due to being **labor-intensive** and less precise. - They reflect a general autoimmune response against various antigens within the **pancreatic islets** rather than a single specific protein. *Anti-glutamic acid decarboxylase (anti-GAD) antibodies* - While **Anti-GAD** antibodies are the **most common** autoantibody in T1DM, present in 70-80% of patients, they are less specific than ZnT8 antibodies. - Anti-GAD antibodies can also be found in other autoimmune conditions, such as **Stiff Person Syndrome** or autoimmune thyroid disease, making them less specific for T1DM alone. *Anti-insulin antibodies (IAA)* - IAA are often the first autoantibodies to appear in very young children with T1DM, especially before insulin therapy, but have **low specificity** if the patient has already received exogenous insulin. - Their diagnostic utility decreases significantly with age and after exposure to insulin, making them less reliable in older adolescents like the patient described. *Anti-insulinoma antigen-2 (IA-2) antibodies* - IA-2 antibodies are present in about 50-70% of newly diagnosed T1DM cases and are associated with **rapid progression** of beta-cell destruction. - While important for diagnosis as part of an autoantibody panel, they do not possess the same level of individual **specificity** for T1DM as Anti-zinc transporter 8 antibodies.
Question 75: A 53-year-old man with type 2 diabetes treated with metformin and sitagliptin has an HbA1c of 69 mmol/mol. His BMI is 32 kg/m² and eGFR is 42 ml/min/1.73m². He has a history of heart failure with reduced ejection fraction diagnosed 2 years ago, currently NYHA class II. Which medication should be added to improve both his glycaemic control and cardiovascular outcomes?
- A. Empagliflozin
- B. Dapagliflozin (Correct Answer)
- C. Canagliflozin
- D. Gliclazide
- E. Exenatide
Explanation: ***Dapagliflozin*** - **Dapagliflozin** is the most appropriate choice due to its proven **mortality benefit** in patients with **heart failure with reduced ejection fraction (HFrEF)**, as demonstrated in the **DAPA-HF** trial. - It is licensed for glycaemic control and cardiovascular benefits in patients with an **eGFR** as low as 25 ml/min/1.73m², making it suitable for this patient's eGFR of 42 ml/min/1.73m². *Empagliflozin* - **Empagliflozin** generally requires an **eGFR >45 ml/min/1.73m²** for initiation when the primary goal is glycaemic control, making it less suitable for this patient's current renal function. - While it provides significant **cardiovascular protection** and benefits in heart failure, its specific initiation threshold for glucose lowering is more restrictive than dapagliflozin in this eGFR range. *Canagliflozin* - **Canagliflozin** is typically initiated in patients with an **eGFR >60 ml/min/1.73m²**, which excludes it from primary use in this clinical scenario given the patient's eGFR of 42. - Although it demonstrates benefits in **diastolic heart failure** and renal progression, it is not the first-line choice given the current **renal impairment** levels. *Gliclazide* - **Gliclazide**, a sulfonylurea, carries a significant risk of **hypoglycaemia** and does not offer any **cardioprotective** or heart failure benefits. - It may also lead to **weight gain**, which is undesirable in a patient with a **BMI of 32 kg/m²** and existing heart failure. *Exenatide* - **Exenatide** (a GLP-1 receptor agonist) is effective for weight loss and glycaemic control but lacks the specific **mortality benefits** seen with SGLT-2 inhibitors in **HFrEF**. - Per clinical guidelines, **SGLT-2 inhibitors** are prioritized over GLP-1 agonists for patients specifically presenting with **heart failure**.
Question 76: A 36-year-old woman is diagnosed with Graves' disease and started on carbimazole 40mg daily. After 3 weeks, she develops a sore throat and fever. Blood tests show white cell count 1.8 × 10⁹/L with neutrophils 0.4 × 10⁹/L. What is the most appropriate immediate management?
- A. Stop carbimazole, admit for IV antibiotics and haematology review (Correct Answer)
- B. Continue carbimazole, prescribe antibiotics in the community
- C. Stop carbimazole, switch to propylthiouracil, prescribe antibiotics
- D. Reduce carbimazole dose to 20mg daily and prescribe antibiotics
- E. Stop carbimazole, arrange urgent thyroidectomy
Explanation: ***Stop carbimazole, admit for IV antibiotics and haematology review*** - The patient's symptoms of **sore throat and fever**, combined with a **neutrophil count of 0.4 × 10⁹/L**, indicate **agranulocytosis**, a severe and life-threatening adverse effect of **carbimazole**. Immediate cessation of the drug is crucial to prevent further bone marrow suppression. - Given the high risk of **sepsis** due to severe neutropenia, urgent **hospital admission** for **broad-spectrum intravenous antibiotics** is mandatory, along with **haematology review** for specialized management and monitoring. *Continue carbimazole, prescribe antibiotics in the community* - Continuing **carbimazole** in the presence of **agranulocytosis** would exacerbate the **bone marrow suppression**, leading to a further drop in neutrophil count and an increased risk of overwhelming **sepsis**. - Managing a patient with **febrile neutropenia** and suspected **agranulocytosis** in the community with oral antibiotics is inappropriate and dangerous due to the high mortality risk associated with severe infection. *Stop carbimazole, switch to propylthiouracil, prescribe antibiotics* - While **propylthiouracil (PTU)** is an alternative antithyroid drug, it has a significant risk of **cross-reactivity** for **agranulocytosis** with **carbimazole**, meaning a patient who develops it with one thionamide is likely to develop it with the other. - Switching to another thionamide is therefore contraindicated, and the priority is to manage the acute agranulocytosis and consider non-thionamide options for Graves' disease later. *Reduce carbimazole dose to 20mg daily and prescribe antibiotics* - **Agranulocytosis** is an **idiosyncratic reaction** to carbimazole, meaning it is not dose-dependent. Reducing the dose will not mitigate the risk or severity of the bone marrow suppression. - Any continued exposure to the offending drug will hinder the recovery of **neutrophil production** and maintain the patient's susceptibility to severe infection. *Stop carbimazole, arrange urgent thyroidectomy* - Although **thyroidectomy** is a definitive treatment for **Graves' disease**, performing surgery on a patient with **severe neutropenia** and active infection (fever and sore throat) carries an extremely high risk of **post-operative complications** and **sepsis**. - The immediate priority is to stabilize the patient's haematological status and control the infection; surgical intervention can only be considered once the **agranulocytosis** has resolved and the patient is medically stable.
Question 77: A 61-year-old woman with type 2 diabetes for 13 years presents with numbness in both feet. Examination reveals absent ankle reflexes, reduced vibration sense to the knees bilaterally, and loss of light touch sensation in a stocking distribution. Monofilament testing is abnormal. Foot pulses are palpable. HbA1c is 74 mmol/mol. Which additional investigation is most important to arrange?
- A. Nerve conduction studies
- B. MRI spine to exclude cauda equina syndrome
- C. Serum B12, folate, and thyroid function tests (Correct Answer)
- D. Ankle-brachial pressure index measurement
- E. Urgent vascular surgery referral
Explanation: ***Serum B12, folate, and thyroid function tests***- In patients with suspected **diabetic peripheral neuropathy**, it is essential to exclude other **reversible causes**; NICE guidelines specifically recommend checking **vitamin B12** and **TSH**.- **Metformin**, commonly used for Type 2 Diabetes, is a known cause of **B12 deficiency**, which can independently cause or exacerbate peripheral neuropathy symptoms.*Nerve conduction studies*- These are generally reserved for **atypical presentations** such as rapid onset, asymmetric symptoms, or when **motor weakness** outweighs sensory loss.- A diagnosis of **diabetic neuropathy** is primarily clinical based on the characteristic **stocking-distribution** and does not require routine electrophysiology.*MRI spine to exclude cauda equina syndrome*- **Cauda equina syndrome** typically presents with acute back pain, **saddle anesthesia**, and bladder/bowel dysfunction, none of which are present here.- The symmetrical, distal sensory loss reaching to the knees is classic for a **length-dependent neuropathy**, not a spinal root compression.*Ankle-brachial pressure index measurement*- ABPI is used to assess for **Peripheral Arterial Disease (PAD)**; however, the patient has **palpable foot pulses**, which makes significant ischemia unlikely.- While PAD often coexists with diabetes, the primary complaint of numbness and the loss of **vibration/monofilament sensation** are neurogenic rather than vascular.*Urgent vascular surgery referral*- Urgent referral is indicated for **limb-threatening ischemia** or acute arterial occlusion, characterized by the '6 Ps' including pulselessness and pallor.- This patient's symptoms are chronic and her **foot pulses are palpable**, indicating that her circulation is currently stable.
Question 78: A 27-year-old woman with type 1 diabetes is admitted with DKA. After 6 hours of treatment with IV fluids and insulin, her glucose falls to 12.4 mmol/L. Venous blood gas shows pH 7.26, bicarbonate 13 mmol/L, ketones 2.8 mmol/L. What is the most appropriate modification to her management?
- A. Switch to subcutaneous insulin and stop IV fluids
- B. Stop insulin infusion and commence subcutaneous insulin
- C. Continue current insulin infusion rate until ketones clear
- D. Add 10% glucose infusion and continue fixed-rate insulin (Correct Answer)
- E. Reduce insulin infusion rate by half
Explanation: ***Add 10% glucose infusion and continue fixed-rate insulin*** - In **Diabetic Ketoacidosis (DKA)**, the fixed-rate insulin infusion must be maintained to suppress **ketogenesis** until ketones are <0.6 mmol/L and pH >7.3, as the patient's current labs (pH 7.26, ketones 2.8 mmol/L) indicate DKA is not yet resolved. - When blood glucose drops below **14 mmol/L** (or 200 mg/dL), a **10% glucose** infusion should be added to prevent **hypoglycemia** while ensuring the insulin continues to clear the **ketosis**. *Switch to subcutaneous insulin and stop IV fluids* - Transition to **subcutaneous insulin** and stopping IV fluids are only appropriate once DKA is fully resolved, meaning pH >7.3, ketones <0.6 mmol/L, bicarbonate >15 mmol/L, and the patient is able to eat. - Prematurely stopping **IV fluids** and the insulin infusion while the patient is still acidotic and ketotic will lead to worsening **dehydration** and rebound **metabolic acidosis**. *Stop insulin infusion and commence subcutaneous insulin* - The **insulin infusion** must not be stopped until the underlying **ketonemia** and **acidosis** have resolved, as indicated by the DKA resolution criteria. - **Subcutaneous insulin** has a slower onset of action and is not effective for managing the acute metabolic derangements and high insulin requirements in active DKA. *Continue current insulin infusion rate until ketones clear* - While continuing the insulin infusion is crucial for clearing ketones, doing so without adding **glucose** once the blood sugar has fallen below **14 mmol/L** will inevitably lead to **iatrogenic hypoglycemia**. - DKA management protocols emphasize maintaining adequate glucose levels to prevent hypoglycemia while simultaneously treating ketosis with insulin. *Reduce insulin infusion rate by half* - Reducing the **Fixed-Rate Intravenous Insulin Infusion (FRIII)** is generally contraindicated as it would slow down the rate of **ketone clearance** and delay the resolution of **acidosis**. - The strategy is to maintain the insulin dose to treat the **ketosis** and adjust the glucose infusion rate to manage blood sugar levels.
Question 79: A 45-year-old woman with newly diagnosed type 2 diabetes attends for advice. Her HbA1c is 58 mmol/mol, BMI 28 kg/m², and eGFR >90 ml/min/1.73m². She has no other comorbidities. Which additional cardiovascular risk assessment is recommended at diagnosis in all patients with type 2 diabetes?
- A. Exercise ECG stress test
- B. Coronary artery calcium score CT
- C. Lipid profile and 10-year cardiovascular risk calculation (Correct Answer)
- D. Echocardiography
- E. 24-hour ambulatory blood pressure monitoring
Explanation: ***Lipid profile and 10-year cardiovascular risk calculation*** - In patients newly diagnosed with **type 2 diabetes**, it is standard of care to perform a formal **lipid profile** and calculate the **10-year CV risk** (e.g., QRISK3) to guide primary prevention. - This assessment helps identify those who require **statin therapy** (typically atorvastatin 20mg) if the calculated risk score meets the threshold of **10%** or higher. *Exercise ECG stress test* - This test is not recommended for **asymptomatic** screening in newly diagnosed diabetes and has high rates of false positives in low-risk individuals. - It is reserved for patients presenting with clinical symptoms of **stable angina** or high-risk cardiac features. *Coronary artery calcium score CT* - **CACS** is used primarily as a tie-breaker in specific cases of intermediate risk but is not a routine part of the baseline diabetic workup. - Clinical guidelines prioritize **calculated risk scores** and metabolic parameters over imaging for initial risk stratification. *Echocardiography* - Routine **echocardiography** is not indicated at the time of diagnosis unless there is clinical evidence of **heart failure**, valvular disease, or **structural heart anomalies**. - While diabetes increases the risk of heart failure, it is not a cost-effective screening tool for asymptomatic patients without physical findings. *24-hour ambulatory blood pressure monitoring* - **ABPM** is useful for confirming a diagnosis of **hypertension** if clinic readings are high, but it is not a mandatory screening tool for all patients. - Initial assessment requires standard **clinic blood pressure** measurements; ABPM is reserved for suspected white-coat hypertension or diagnostic uncertainty.
Question 80: A 58-year-old man with type 2 diabetes for 11 years attends for annual review. He takes metformin and empagliflozin. HbA1c is 52 mmol/mol. Fundoscopy shows multiple dot and blot haemorrhages and hard exudates within one disc diameter of the fovea in both eyes, but visual acuity is 6/6 bilaterally. What is the classification of his diabetic retinopathy and appropriate management?
- A. Mild non-proliferative retinopathy; continue annual screening
- B. Moderate non-proliferative retinopathy; increase screening to 6-monthly
- C. Diabetic maculopathy; urgent ophthalmology referral within 1 week (Correct Answer)
- D. Severe non-proliferative retinopathy; routine ophthalmology referral
- E. Proliferative retinopathy; urgent ophthalmology referral within 1 week
Explanation: ***Diabetic maculopathy; urgent ophthalmology referral within 1 week*** - The presence of **hard exudates** or haemorrhages within **one disc diameter of the fovea** defines diabetic maculopathy, a sight-threatening condition. - Even with preserved **visual acuity** (6/6), the location of these lesions necessitates **urgent ophthalmology referral** to prevent irreversible vision loss. *Mild non-proliferative retinopathy; continue annual screening* - **Mild NPDR** is characterized by microaneurysms only; the presence of **hard exudates** near the fovea signifies a more advanced and urgent condition. - Annual screening is insufficient when lesions are within the macular area, as this risks progression to **macular oedema** and vision impairment. *Moderate non-proliferative retinopathy; increase screening to 6-monthly* - While dot and blot haemorrhages can be seen in **moderate NPDR**, the critical finding here is the proximity of **hard exudates** to the fovea, which defines **maculopathy**. - Increasing screening frequency is inadequate; the patient requires active assessment for **laser therapy** or **anti-VEGF injections** to treat the maculopathy. *Severe non-proliferative retinopathy; routine ophthalmology referral* - **Severe NPDR** is diagnosed by the "4-2-1 rule" (severe haemorrhages in 4 quadrants, venous beading in 2, or intraretinal microvascular abnormalities (IRMA) in 1), which is not fully described. - A routine referral is too slow for potential maculopathy; **urgent intervention** is crucial to prevent foveal involvement and permanent vision loss. *Proliferative retinopathy; urgent ophthalmology referral within 1 week* - **Proliferative retinopathy** is characterized by the presence of **neovascularization** (new vessel formation) on the optic disc or elsewhere in the retina, which is not mentioned in the patient's fundoscopy. - While both conditions warrant urgent referral, the specific fundoscopic findings (hard exudates near the fovea) specifically point to **diabetic maculopathy** rather than proliferative changes.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free